HROW

Harrow, Inc.

$30.36

10.52%
SectorHealthcareIndustryDrug Manufacturers - Specialty & GenericCountryUnited States

Harrow, Inc., an eyecare pharmaceutical company, engages in the discovery, development, and commercialization of ophthalmic pharmaceutical products in the United States. It operates through Branded and ImprimisRx segments. The company offers ImprimisRx, an ophthalmology-focused compounded medications.

Source: Yahoo Finance
AI summary

Price & performance

1M+3.4%
3M-25.4%
YTD-39.2%
1Y-11.1%
52-week range—
Beta1.53
Full chart and returns against a benchmark

Q-Score

56/ 100

Quality against peers; 50 is the peer median.

Growth73
Risk56
Performance57
Valuation40
Profitability58
Leverage36
Sentiment61
Every score and metric

News sentiment

Open News

Latest results · FY 2025

Revenue$272.3M+36.4%
Net income-$5.1M
Net margin-1.9%+6.9 pts
Historical fundamentals

Red flags in filings

1active red flag
Auditor changeSep 19, 2025
Filings, findings and the timeline

Revenue exposure

0%of revenue from outside the US
United States100%
Largest customer10%
Regions, segments, customers and suppliers

Valuation

HROWIndustryP/E—35.25P/S3.752.74EV/EBITDA—16.35P/B38.992.46PEG—0.87
Dividend yield0.00%
Every valuation metric

Earnings

Nov 9next report, after the close
EPS estimate$0.32
Beats (last 4 quarters)—
Average surprise—
EPS revisions (30d)—
Every quarter against its estimate